Efficacy and safety of iota-carrageenan nasal spray versus placebo in early treatment of the common cold in adults: the ICICC trial.

Conclusions The primary endpoint did not demonstrate a statistically significant difference between I-C and placebo but showed a trend towards I-C benefit.

also in 53,322 other papers

For the viruses quantified with the panenterhino/Ge/08 assay, there was a more substantial reduction in virus load in the I-C group (90.2 % compared with 72.0 % for placebo), although this did not reach statistical significance (Table 6 ).

also in 111,027 other papers

In the ICICC trial, although the primary endpoint TSS 2–4 did not demonstrate a statistically significant difference between I-C and placebo, there was a clear trend towards benefit of I-C treatment.

also in 19,460 other papers